Form 4: Vigil Neuroscience Director Disposes Shares Post-Merger

A director of Vigil Neuroscience, Gerhard Koenig, disposed of common stock and stock options following the company's acquisition by Sanofi.

Summary

• Gerhard Koenig, a Director at Vigil Neuroscience, Inc. (VIGL), reported the disposition of 5,000 shares of common stock and multiple tranches of stock options totaling 109,175 underlying shares.
• The dispositions occurred on August 5, 2025, which was the effective time of the merger between Vigil Neuroscience, Inc. and Vesper Acquisition Sub Inc., a wholly-owned subsidiary of Sanofi.
• Under the merger agreement, each outstanding share of Vigil Neuroscience common stock was converted into the right to receive $8.00 per share in cash (the 'Closing Amount') plus one contingent value right (CVR).
• Each CVR represents the right to receive an additional $2.00 in cash, conditioned upon the satisfaction of a specific clinical milestone.
• Unvested Restricted Stock Units (RSUs) held by the reporting person were accelerated, fully vested, and converted into the right to receive the Closing Amount and one CVR per share.
• Unvested stock options with an exercise price less than the Closing Amount were also accelerated, fully vested, and converted into a cash amount equal to the product of the number of shares subject to the option multiplied by the difference between the Closing Amount and the exercise price, plus one CVR per share.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful completion of a merger providing liquidity and a potential upside for shareholders, and the acceleration of equity awards for the reporting person. The contingent nature of the CVR introduces a minor element of uncertainty, preventing a higher score.

Positives

• The merger provides a clear exit strategy and liquidity for shareholders, including the reporting person.
• Unvested Restricted Stock Units (RSUs) and stock options were accelerated and fully vested upon the merger's effective time, providing immediate value to the director.
• The potential for an additional $2.00 per share via the Contingent Value Right (CVR) offers upside if the clinical milestone is met.

Negatives

• The company, Vigil Neuroscience, Inc., ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Sanofi.
• The value of the Contingent Value Right (CVR) is conditional and not guaranteed, depending on the achievement of a specific clinical milestone.

Risks

• The Contingent Value Right (CVR) payment of $2.00 per share is contingent upon the satisfaction of a specific clinical milestone, meaning the full $10.00 per share consideration is not guaranteed.
• There is no public market for the CVRs, and they are not transferable except in limited circumstances, which could limit their liquidity and valuation.

Future Outlook

The future outlook for former Vigil Neuroscience shareholders includes the potential to receive an additional $2.00 per share via a Contingent Value Right (CVR), contingent upon the achievement of a specific clinical milestone. The company itself will operate as a wholly-owned subsidiary of Sanofi.

Industry Context

This merger represents a common strategy in the biotechnology and pharmaceutical industry where larger pharmaceutical companies acquire smaller biotech firms to gain access to promising drug candidates, pipelines, and intellectual property. Such acquisitions often involve upfront cash payments combined with contingent value rights tied to clinical or regulatory milestones, allowing the acquirer to mitigate risk while providing potential upside for the acquired company's shareholders.

Comparison to Industry Standards

• The structure of the acquisition, combining an upfront cash payment ($8.00 per share) with a contingent value right (CVR) for an additional $2.00 per share, is a common practice in biotech mergers and acquisitions.
• Similar deals include Bristol Myers Squibb's acquisition of MyoKardia, which also included an upfront cash payment for shares, and various other biotech buyouts where milestone payments are used to bridge valuation gaps and share risk.
• The acceleration and vesting of unvested equity awards (RSUs and stock options) upon the merger's effective time is standard practice in change-of-control provisions to ensure executive and employee alignment and compensation.

Stakeholder Impact

• Shareholders: Received $8.00 per share in cash and one CVR per share, with potential for an additional $2.00 per share.
• Employees (including the reporting director): Unvested equity awards (RSUs and stock options) were accelerated and fully vested, providing immediate financial benefit.

Next Steps

• Monitoring the progress towards the clinical milestone required for the Contingent Value Right (CVR) payment.

Key Dates

Keywords

Vigil Neuroscience, VIGL, Sanofi, Merger, Acquisition, Form 4, SEC filing, Stock options, Restricted Stock Units, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals